SHAREHOLDERS in the biopharmaceutical company Renovo have been advised to abstain from approving a remuneration report which it is claimed could lead to executives taking "risky decisions".
Governance watchdog Pensions Investments Research Consultants is concerned over a resolution to increase the maximum award available under the firm’s long term incentive scheme. PIRC are also co...
To continue reading this article...
Join Professional Pensions
Become a Professional Pensions Lite Member today
- Three complimentary articles per month covering the latest real-time news, analysis and opinion from the industry
- Receive important and breaking news stories via our two daily news alerts
- Hear from industry experts and other forward-thinking leaders